Monoclonal Antibodies: A Segment of Major GrowthCHI Insight Pharma ReportsMarch 1, 2011 SKU: CHI6169277 |
- Executive Sumary
- Chapter 1
- INTRODUCTION
- 1.1. Introduction
- 1.2. Regulatory Background
- 1.3. Technology Background
- What is an Antibody?
- What is a Monoclonal Antibody?
- Advantages and Disadvantages
- of Monoclonal Antibodies
- Chapter 2
- KEY TECHNOLOGIES
- 2.1. Introduction
- 2.2. Murine-Derived Monoclonal
- Antibodies
- 2.3. Chimeric Monoclonal Antibodies
- 2.4. Humanized Monoclonal Antibodies
- 2.5. Fully Human Monoclonal Antibodies
- 2.6. Antibody Fragments
- 2.7. Modified Antibodies
- Labeled Antibodies
- Conjugated Antibodies
- Chapter 3
- COMMERCIALIZED MONOCLONAL
- ANTIBODIES
- 3.1. Overview
- Commercial Impact
- 3.2. Oncology Therapeutics
- RITUXAN
- Herceptin
- Avastin
- ERBITUX and Vectibix
- Campath
- ARZERRA
- Targeted Antibodies
- 3.3. Inflammatory and Autoimmune
- Diseases
- REMICADE, HUMIRA, CIMZIA,
- and SIMPONI
- ACTEMRA and STELARA
- XOLAIR
- ILARIS
- 3.4. Other Indications
- Synagis
- TYSABRI
- Soliris
- ReoPro
- LUCENTIS
- Prolia
- Orthoclone OKT3, Simulect, and
- ZENAPAX for Transplant Rejection
- 3.5. Labeled Antibodies
- 111Indium-Labeled Antibodies
- 99mTechnetium-Labeled Antibodies
- Chapter 4
- MONOCLONAL ANTIBODIES IN THE PIPELINE: ONCOLOGY
- 4.1. Introduction
- 4.2. Antibodies in Advanced Development
- Ipilimumab
- Girentuximab
- Brentuximab
- Pertuzumab
- Trastuzumab Modifications
- Obinutuzumab
- Necitumumab
- Zalutumumab
- Nimotuzumab
- Ramucirumab
- Zanolimumab
- Abagovomab
- Farletuzumab
- RIG-Scan CR
- 4.3. Antibodies in Phase II Development
- Tyrosine Kinase-Linked Receptors
- IGF1R
- EGFR
- HGFR
- Other Growth Factor Receptors
- Chemokines and Cytokines
- Cell Adhesion Targets
- Death Domain Targets
- Cytotoxic Conjugates
- Radioimmunotherapeutics
- Multiple Myeloma
- Leukemia and Lymphoma
- Melanoma and Mesothelioma
- Other Oncology Indications
- 4.4. Early-Stage Development Antibodies
- 4.5. Overview
- Chapter 5
- 5.1. Introduction
- 5.2. Antibodies in Advanced Development
- Belimumab
- Briakinumab
- Reslizumab
- Epratuzumab
- Vedolizumab
- Ocrelizumab
- T-1h
- SAR-153191 (REGN-88)
- LY-2127399
- 5.3. Antibodies in Phase II Development
- Rheumatoid Arthritis
- Mavrilimumab, MOR-103, and KB-003
- BMS-945429, CNTO-136, and CDP-6038
- BT-061, NN-8855, RG-7416, and NNC-0151- 0000-0000
- Otelixizumab
- GSK-315234
- MDX-1100
- AMG-108
- Asthma
- IL-13 Antagonists
- MedImmune’s Benralizumab and Enokizumab
- Mepolizumab
- RG-4930
- RG-7449
- Psoriasis
- Fezakinumab
- CNTO-1959
- IL-17 Antagonists
- AIN-457
- AMG-827
- LY-2439821
- Other Indications
- Siltuximab
- Rontalizumab and Sifalimumab
- Bertilimumab
- 5.4. Early-Stage Development Antibodies
- Chapter 6
- 6.1. Introduction
- 6.2. Metabolic Disorders
- Diabetes
- Teplizumab
- Diabetic Nephropathy
- Hypercholesterolemia
- Ocular Diseases
- 6.3. CNS Disorders
- Pain
- Alzheimer’s Disease
- Antibodies in Phase I and II Development
- Bapineuzumab (Phase III)
- Solanezumab (Phase III)
- 6.4. Infectious Diseases
- Antibacterial Antibodies
- Antiviral Antibodies
- 6.5. Other Indications
- Chapter 7
- EMERGING NEW TECHNOLOGIES
- 7.1. Introduction
- 7.2. Modified Antibodies
- PEGylation
- Cytotoxic Conjugates
- 7.3. Antibody Engineering
- 7.4. Therapeutic Profile Enhancements
- Chapter 8
- MAJOR COMPANIES
- 8.1. Introduction
- 8.2. The Key Players
- Roche
- Abbott
- Johnson & Johnson
- Merck
- Biogen Idec
- Novartis
- AstraZeneca
- 8.3. Other Companies
- Eli Lilly
- Bristol-Myers Squibb
- Amgen
- 8.4. Response of Other Major Pharma
- Chapter 9
- TECHNOLOGY-FOCUSED COMPANIES
- Introduction
- 9.1. Adimab
- 9.2. Alder Biopharmaceuticals
- 9.3. Biosynexus
- 9.4. Celldex Therapeutics
- 9.5. GANYMED Pharmaceuticals
- 9.6. Genmab
- 9.7. Human Genome Sciences
- 9.8. ImmunoGen
- 9.9. Innate Pharma
- 9.10. MorphoSys
- 9.11. Morphotek
- 9.12. PanGenetics
- 9.13. PDL BioPharma
- 9.14. Perseis Therapeutics
- 9.15. Seattle Genetics
- 9.16. ToleRx
- 9.17. Trillium Therapeutics
- 9.18. TRION
- 9.19. UCB
- 9.20. Wilex
- 9.21. XOMA
- Chapter 10
- COMMERCIAL OUTLOOK
- 10.1. General Perspective
- 10.2. Market Development
- Oncology
- Inflammatory & Autoimmune Diseases
- Emerging Indications
- 10.3. Threats
- Reimbursement Constraints
- Biosimilars
- Technology
- 10.4. Overall Outlook
- References
- Glosary
- Compan y Index with Web Addreses
- Figures and Tables
- Figure 1.1. Schematic Structure of an Antibody
- Figure 2.1. Progression in the Development of Therapeutic Monoclonal Antibodies
- Figure 3.1. Accelerating Rate of US Approvals of Monoclonal Antibodies, 1986-2010
- Figure 5.1. Antibodies in Development for Inflammatory & Autoimmune Disorders by Indication
- Figure 8.1. 2009 Monoclonal Antibody Sales: Market Share by Company
- Figure 10.1. Generic SWOT Analysis for Monoclonal Antibodies
- Figure 10.2. Anticipated Approval Dates For New Monoclonal Antibodies, 2011-2015
- Table 2.1. Marketed Monoclonal Antibodies by Type
- Table 3.1. Reported 2009 Sales of Approved Monoclonal Antibodies
- Table 3.2. Differentiation of the Approved Anti-TNF Antibodies
- Tables 4.1-4.15. Monoclonal Antibodies in Clinical Development for Oncology Indications
- Tables 5.1-5.3. Monoclonal Antibodies in Clinical Development for Inflammatory & Autoimmune Indications
- Table 6.1-6.4. Monoclonal Antibodies in Clinical Development for Metabolic, CNS,Infectious Disease, Cardiovascular, and Other Indications
- Tables 8.1-9.16. Company Antibody Development Pipelines
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Antibody Technologies Reports